Factor IXa Inhibitors as Novel Anticoagulants

E. L. Howard, K. C.D. Becker, C. P. Rusconi, R. C. Becker
2007 Arteriosclerosis, Thrombosis and Vascular Biology  
Currently available anticoagulants are limited by modest therapeutic benefits, narrow clinical applications, increased bleeding risk, and drug-induced thrombophilia. Because factor IX plays a pivotal role in tissue factor (TF)-mediated thrombin generation, it may represent a promising target for drug development. Several methods of attenuating factor IX activity, including monoclonal antibodies, synthetic active site-blocked competitive inhibitors, oral inhibitors, and RNA aptamers, have
more » ... ne investigation. This review summarizes present knowledge of factor IX inhibitors with emphasis on biology, pharmacology, preclinical data, and early-phase clinical experience in humans. (Arterioscler Thromb Vasc Biol. 2007;27:722-727.)
doi:10.1161/01.atv.0000259363.91070.f1 pmid:17272750 fatcat:u5m2lh6he5er3cgh23zjhhx46u